I L T I M O

ILTIMO company is developing an original drug for skin rejuvenation and regeneration. The mechanism of action is based on stimulation of fibroblasts and improvement of microcirculation via FGF/FGFR signaling. We have successful experience in studying this signaling, described in research articles. Stage of project: Preclinical

Preclinical studies of our humanized anti-FGFR1 monoclonal antibody have shown promising results. The planned phase 1/2 clinical trial will assess safety and preliminary efficacy of antibody in patients with FGFR1-positive metastatic cancers who have exhausted standard therapy. Stage of project: Clinical

Our company works according to the principle of individual approach based on molecular changes. This method allows us to succeed in tasks of any level. The authors of our projects have success stories in developing of molecular therapeutics that were transferred to big pharma.